Innate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 27, 2025 Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 ...
US FDA approves Sanofi's bleeding disorder therapy
The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...
BioPharma Dive2d
FDA broadens use of Novartis’ radiopharma drug Pluvicto
Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...
The American Journal of Managed Care2d
FDA Approves Fitusiran for Reducing Bleeds in Patients With Hemophilia A/B
Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...
Sanofi’s Easier to Use Hemophilia Drug Approved by US FDA
Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) ...
Pharmaceutical Technology3d
How bioconjugation is unlocking the next generation of drug development
Bioconjugation presents an new frontier for pharmaceutical development, providing an option for improved drug efficacy across ...
Zacks Investment Research on MSN4d
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
Shares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, ...
EQS-News: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 ...
Le Lézard5d
Theratechnologies Receives FDA Approval for EGRIFTA WRtm (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the ...